NeOnc Shares Move Up With Key Brain Cancer Trial Updates Ahead
NeOnc Technologies Holdings Inc. was last up 6.7% at $4.87 in late trading Friday. The brain-cancer drug developer’s shares added 30.5 cents, after hitting a range between $4.64 and $4.90 on about 33,500 shares traded. The Nasdaq name now carries a market cap of roughly $113 million. Why it matters now: NeOnc's next catalysts are clinical trial results and regulatory updates rather than earnings. On May 18, the company said NEO212 finished Phase 1 dose escalation and set the Phase 2 dose at 610 mg. Interim data from the fully enrolled Phase 2a trial for NEO100 in recurrent IDH1-mutant high-grade glioma are due around August. CEO Amir Heshmatpour said the quarter was “a transformational period.”
